DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic
DocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved
How this was made
The 30-second read
Why it matters
The key trading takeaway is a deterioration in full-year adjusted EBITDA loss guidance and weaker revenue/margins, countered by management’s detailed plan to reach breakeven by end of 2026 and acquisition-related growth and cross-sell rationale.
Market read
Traders should focus on the updated EBITDA loss range, margin headwinds (fuel, wages, SteadyMD), cash/receivables uncertainty, and whether Hicuity closing and synergy timing stay on track.
What to watch
Cash availability and migrant receivables collection uncertainty could be more constraining than the company’s breakeven run-rate narrative, and Hicuity closing timing could slip beyond management’s synergy assumptions.
Background
DocGo reported Q2 2026 call highlights and discussed full-year 2026 adjusted EBITDA guidance, segment margin drivers, cash position, and the pending Hicuity acquisition.
Ticker impact
DocGo widened full-year 2026 adjusted EBITDA loss guidance to $17M-$22M, citing slower cost cuts and lower gross margins.
Near-term bias negative, with volatility driven by confidence in cost-cut execution, margin normalization, and Hicuity closing/synergy timing.
The article provides specific, time-bound guidance changes (EBITDA loss range), margin drivers (fuel, wages, SteadyMD), and acquisition closing hurdles (state approvals and customer consents) that directly affect DCGO’s earnings trajectory.
Market effects
Reinforces margin sensitivity in medical transportation and virtual care to wage and fuel costs, and highlights regulatory reimbursement risk concentration in RPM.
No specific regional impact disclosed.
Primarily US healthcare services reimbursement and state regulatory approvals; limited global spillover.
Counterpoint
The EBITDA loss widening may be largely temporary, with management pointing to normalization of SteadyMD margins and sequential SG&A declines as severance rolls off.
Key entities
- companyDocGo Inc
NASDAQ-listed healthcare services provider discussing Q2 results, updated 2026 EBITDA guidance, and the Hicuity acquisition.
- companyHicuity Health
Target of DocGo’s acquisition, with management citing low double-digit revenue growth and standard regulatory/customer consents for closing.
- regulatorCMS (Medicare)
Proposed rule may limit Medicare reimbursement for RPM in 2027, which management argues is largely not applicable to DocGo’s CCM/TCM model.
